[
    [
        {
            "time": "2020-11-04",
            "original_text": "Novo Nordisk, Trading Near Highs, Announces $1.8 Billion Acquisition",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Trading Near Highs",
                    "Acquisition",
                    "$1.8 Billion"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk, Trading Near Highs, Announces $1.8 Billion Acquisition",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-11-05",
            "original_text": "Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Trading",
                    "Board Members",
                    "Executives",
                    "Associated Persons"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Trading in Novo Nordisk shares by board members, executives and associated persons on 4 and 5 November 2020",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 3,
                "Headline_Structure": 5,
                "Source_Recency": 2
            }
        },
        {
            "time": "2020-11-05",
            "original_text": "(EMIS) Alert: Johnson Fistel Investigates Proposed Sale of Emisphere; Are Shareholders Getting a Fair Deal?",
            "features": {
                "keywords": [
                    "EMIS",
                    "Johnson Fistel",
                    "Proposed Sale",
                    "Emisphere",
                    "Shareholders",
                    "Fair Deal"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "(EMIS) Alert: Johnson Fistel Investigates Proposed Sale of Emisphere; Are Shareholders Getting a Fair Deal?",
                "Correlation": 7,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-11-05",
            "original_text": "Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Pill-Form",
                    "Diabetic Drugs",
                    "$1.8 Billion Deal"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novo Nordisk to boost pill-form diabetic drugs with $1.8 billion deal",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]